We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Native Antigens to Improve Diagnostic Testing for Human Metapneumovirus

Read time: Less than a minute

 First isolated in 2001, hMPV in an important cause of community-acquired acute respiratory infection.  Serious illness may occur in the very young and in those who are chronically ill or immunosuppressed. The identification of hMPV infection has predominantly relied on real-time PCR which can be time consuming and costly.  The availability of this native antigen provides the in-vitro diagnostic manufacturer with the opportunity to develop cost effective test kits based  upon rapid lateral flow and ELISA formats.

Dr Nick Roesen, NAC’s Scientific Director said ““Our hMPV A and B native antigens are identical to the virus itself as it appears in the patient and this means that IVD manufacturers can now develop rapid tests which offer the highest levels of sensitivity and specificity to the infection.”

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.